KENILWORTH, N.J.–(BUSINESS WIRE) May 5, 2021– Merck (NYSE: MRK), known
Read moreHome »
Merck Presents Three-Year Survival Data for Keytruda (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With Keytruda in Advanced Non‑Small Cell Lung Cancer
KENILWORTH, N.J.–(BUSINESS WIRE) October 16, 2020 — Merck (NYSE: MRK),
Read more